Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 18Active not recruiting 13Completed 5Not yet recruiting 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Breast Neoplasms 360Neoplasms 255Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 183Lung Neoplasms 152Prostatic Neoplasms 151Carcinoma, Hepatocellular 128Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 84Neoplasm Metastasis 74Recurrence 71Uterine Cervical Neoplasms 69Rectal Neoplasms 68Stomach Neoplasms 65Ovarian Neoplasms 65Triple Negative Breast Neoplasms 60Squamous Cell Carcinoma of Head and Neck 57Head and Neck Neoplasms 54Glioblastoma 54Brain Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47Melanoma 44Esophageal Neoplasms 43Disease 43Colonic Neoplasms 42Hematologic Neoplasms 41Glioma 40

Interventions

nilotinib 1bosutinib 1asciminib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Myeloid, Chronic-Phase × 1 year × Clear all
NCT07454850 2026-05-18

A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait

Novartis

Not yet recruiting
400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07489755 2026-03-24

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Shenzhen TargetRx Co., Ltd.

Phase 3 Not yet recruiting
180 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07091019 2025-07-29

ASC4REAL-2

Novartis

Not yet recruiting
1,000 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡